Press Releases

Beckman Coulter and MeMed to Expand Access to Proven Host Immune Response Diagnostic Able to Distinguish Between Bacterial and Viral Infections

January 31, 2023

Tulsa ER & Hospital Adopts Trailblazing MeMed BV Test

December 22, 2022

Tucson ER & Hospital Adopts Trailblazing MeMed BV Test

October 25, 2022

Dr. Sergey Motov at Maimonides Medical Center to Host Webinar on Using MeMed BV® in the Emergency Department to Rapidly Differentiate Bacterial and Viral Infections

July 13, 2022

MeMed to Participate in Upcoming Conferences

April 29, 2022

MeMed to Host Webinar on Best Practice Clinical Use of MeMed BV® for Differentiating Viral from Bacterial Infections on April 28, 2022

April 21, 2022

MeMed to Host Integrated Symposium at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference 23 April 2022

April 13, 2022

Fierce Medtech Names MeMed as One of its ‘Fierce 15’ Medical Technology Companies

March 07, 2022

MeMed Raises $93M to Accelerate Commercialization of its Host Immune-Response Product Portfolio

January 10, 2022

Clinical Data Published in Clinical Microbiology and Infection Support Use of MeMed’s Test in Reducing Antibiotic Overuse in Children

December 01, 2021

DiaSorin Launches LIASON® MeMed BV®, the First High Throughput Blood Test to Differentiate Between Bacterial and Viral Infections, in Countries Accepting the CE Mark

November 23, 2021

FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV Test and MeMed Key Platform

September 20, 2021

MeMed Named a Finalist for AACC’s Disruptive Technology Award for MeMed COVID-19 Severity Test

August 05, 2021

MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in COVID-19 Patients

July 27, 2021

MeMed Key Wins Red Dot Award for High Design Quality

April 21, 2021

Tanya Gottlieb, VP Scientific Affairs at MeMed, Appointed to the Board of the AMR Industry Alliance

April 19, 2021

MeMed and 360Dx Bring Together International Experts for a Timely Discussion on Predicting COVID-19 Severity Using the Host Immune Response

April 13, 2021

Riwat Lim Joins MeMed Team as Head of Commercial, Europe

January 19, 2021

Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S.

January 11, 2021

MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors

December 26, 2020

DiaSorin and MeMed Partner to Develop and Commercialize Novel Host Immune Response Based Diagnostics Solution

September 08, 2020

MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in COVID-19 Patients

July 23, 2020

MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV Test and MeMed Key Point-of-Need Platform

June 02, 2020

MeMed Advances Diagnostic Solutions for COVID-19 Pandemic to Enable Enhanced Patient Management

May 25, 2020

Diagnostics Industry Veteran Dr. Frédéric Sweeney Joins MeMed as Chief Business Development Officer

October 12, 2019

Contact Us

7 Nahum Het St., Tirat Carmel
Park High-Tech North, 3508506, Israel +972-4-8500302
200 Brickstone Sq., Ste.106
Andover, MA 01810, USA +1-888-203-4550
Linkedin